Key Highlights
- James F. Amatruda, M.D., Ph.D., appointed Director of the Cancer and Blood Disease Institute at CHLA.
- New Chief of Hematology-Oncology, leading clinical care, research, and education programs.
- Advancing pediatric oncology, with a focus on safer, more effective therapies for children.
- CHLA ranked No. 1 in California for pediatric cancer and blood disease care by U.S. News & World Report.
Source: Business Wire
Notable Quote
- “We are thrilled to welcome Dr. Amatruda as the new Director of the Cancer and Blood Disease Institute and Chief of the Division of Hematology-Oncology at CHLA.” — Dr. Alan S. Wayne, Pediatrician-in-Chief at CHLA
SoHC's Take
Dr. James F. Amatruda’s appointment as Director of the Cancer and Blood Disease Institute at CHLA is a significant milestone for the institution and the broader field of pediatric oncology. His extensive research background, particularly in zebrafish-based disease models and translational research, positions CHLA to further solidify its reputation as a leader in pediatric cancer treatment and research. This leadership change is expected to drive the development of new, more effective therapies, underscoring CHLA’s commitment to advancing pediatric healthcare.
